Virginia subcommittee narrowly advances bill to create Prescription Drug Affordability Review Board

A House Labor and Commerce subcommittee advanced House Bill 483 on a 5–4 vote after hours of testimony and amendment, sending the measure to the Appropriations Committee for further review.

Delegate Delaney, the bill’s patron, told the subcommittee the board is designed to rein in high prescription costs while starting narrowly: "We will start this board with policies that we know work," she said, explaining the bill would initially set upper payment limits (UPLs) tied to Medicare‑negotiated prices for the 25 drugs already addressed by federal action. She added that the board would revisit expansion in 2028.

Why this matters: supporters argued the measure would deliver immediate price relief by leveraging federal negotiation outcomes and ensure savings flow to patients. Jared Calvi of AARP Virginia said the bill would "automatically set upper payment limits that are tied to the Medicare negotiated prices," and called the change a way to deliver relief quickly. Several patient‑advocacy groups and medical societies testified that unaffordable drugs result in worse health outcomes.

Opponents — including pharmaceutical and biotechnology trade groups, a rare‑disease advocacy group and business organizations — warned that the bill’s UPL mechanism could prompt PBMs and plans to restrict access or shift utilization, potentially undermining clinical care and investment in drug development. Chris White, speaking for pharmaceutical interests, said other states’ experiences have been mixed and urged caution. Mike Egan of the Rare Access Action Project cautioned that UPLs can be "unworkable" in practice because they may not control acquisition costs.

Key provisions and scope: the committee‑approved substitute narrows initial authority to drugs targeted by the federal Inflation Reduction Act, creates an exemption for rare‑disease drugs used solely for rare conditions, requires the board to engage stakeholders and emphasize transparency, and includes language to protect pharmacist reimbursement and allow some ERISA plans to opt out of UPLs. Delegate Delaney said the draft tightens eligibility for board membership to reduce conflicts of interest.

Process and next steps: the bill passed the subcommittee on a 5–4 roll call and was reported and referred to the Appropriations Committee for funding and fiscal review. Supporters said the board’s early focus on federally negotiated drugs is a pragmatic step; opponents urged more study or different mechanisms to avoid unintended access limits.

The subcommittee’s debate highlighted a central tension: whether state price‑setting tools can reduce out‑of‑pocket costs without causing payers or PBMs to restrict access. The Appropriations Committee will review the fiscal impacts and any implementation details before the bill advances.